1-3 of 3
Günther Fingerle-Rowson
Close
Sort by
Journal Articles

TP53 Mutations and Outcome After Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial of the GCLLSG.

Thorsten Zenz, Patrick Hoth, Raymonde Busch, Hanne Helfrich, Dirk Winkler, Andreas Bühler, Nancy Patten, Sim Truong, Lin Wu, Günther Fingerle-Rowson, Kirsten Fischer, Anna-Maria Fink, Ulrich Jäger, Sebastian Böttcher, Michael Kneba, Michael K. Wenger, Myriam Mendila, Michael Hallek, Hartmut Döhner, Stephan Stilgenbauer
Journal: Blood
Blood (2009) 114 (22): 1267.
https://doi.org/10.1182/blood.V114.22.1267.1267
Published: 2009
Journal Articles

Genomic Aberrations, VH Mutation Status and Outcome after Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial

Stephan Stilgenbauer, Thorsten Zenz, Dirk Winkler, Andreas Bühler, Raymonde Busch, Günther Fingerle-Rowson, Kirsten Fischer, Anna- Maria Fink, Ulrich Jäger, Sebastian Böttcher, Michael Kneba, Michael Wenger, Myriam Mendila, Michael Hallek, Hartmut Döhner
Journal: Blood
Blood (2008) 112 (11): 781.
https://doi.org/10.1182/blood.V112.11.781.781
Published: 2008
Journal Articles

Consolidation with Alemtuzumab in First Remission Induces Pronounced MRD Reduction and Clinical Remissions - Update on a Randomized Phase III Trial of the German CLL Study Group (GCLLSG).

Matthias Ritgen, MD, C. Schweighofer, MD, Günther Fingerle-Rowson, MD, Barbara Eichhorst, MD, Raimunde Busch, Stephan Stilgenbauer, MD, Hartmut Döhner, MD, Michael Kneba, MD, PhD, Michael Hallek, MD, Clemens M. Wendtner, MD
Journal: Blood
Blood (2004) 104 (11): 2506.
https://doi.org/10.1182/blood.V104.11.2506.2506
Published: 2004